Aspen has underlined previously its commitment to building on its business in China, and now it has done so, picking up Sandoz’s local operations for up to €92.6m, while bringing in cash by offloading a quartet of anesthetics in Europe back to the firm.
South Africa’s Aspen Pharmacare believes it has taken a “major step in our stated strategic objective of increasing our presence in China,” after striking a deal to acquire Sandoz’s business in China, including the unit’s pipeline and a portfolio of products, for up to €92.6m ($100m).
At the same time, Sandoz has agreed to strengthen its hospital drugs footprint after agreeing to buy from Aspen...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
